Aethlon Medical, Inc. (AEMD) 股票分析

公司概述

Aethlon Medical, Inc. operates as a medical therapeutic company dedicated to the development of novel immunotherapeutic devices designed to treat cancer and viral infections within the United States market. The firm functions within the Healthcare sector, specifically targeting the Medical Devices industry, where its focus lies in advancing clinical-stage technologies such as the Hemopurifier intended for oncology and life-threatening viral applications. As of the latest available data, the company maintains a market capitalization of $3.48 million, employs a workforce of 9 individuals, and reports N/A for its trailing twelve-month revenue. The minimal market cap figure indicates that Aethlon Medical is a micro-cap entity with limited liquidity and trading volume, while the absence of reported revenue suggests the company is currently in a pre-commercialization or early-stage development phase rather than generating significant sales. The small employee count of 9 further contextualizes the organization's nascent scale, implying that the current business model relies heavily on research and development expenditures rather than established commercial operations or large-scale manufacturing infrastructure.

财务健康

The company's financial performance for the trailing twelve months shows N/A revenue, a net income loss of $-11,522,096, and an EBITDA of $-7,007,023. The substantial gap between the reported N/A revenue and the significant net loss of $-11,522,096 reveals a cost structure driven entirely by operational expenses and research costs rather than product sales, as the company has not yet transitioned to a profitable revenue-generating model. Free cash flow stands at $-4,544,826, indicating that the company is consuming cash reserves to fund its development activities, which severely limits its financial flexibility and necessitates ongoing capital raising or cash burn management. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting the current lack of revenue to generate positive margins and highlighting the company's status as a cash-burning entity with no established profit generation capability. In terms of liquidity and leverage, Aethlon Medical holds $6.96 million in cash against $417,522 in debt, resulting in a debt-to-equity ratio of 6.22, which suggests a leveraged balance sheet structure despite the high cash balance, primarily because equity value is diluted by losses. The current ratio of 5.68 indicates strong short-term liquidity relative to immediate obligations, suggesting the company can meet its short-term liabilities without difficulty in the near term. Return on Equity is reported at -208.6% and Return on Assets at -62.9%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently due to the heavy investment in unproven clinical-stage technologies rather than generating returns.

估值评估

The valuation metrics for Aethlon Medical, Inc. include a P/E Ratio (TTM) of N/A and a Forward P/E of -2.27. The existence of a negative forward P/E while the trailing P/E is unavailable implies that analysts or the market is pricing in continued negative earnings, with the forward metric suggesting a potential path to profitability or a specific forward-looking earnings estimate that remains negative. The Price to Book ratio is 0.32, indicating that the market is valuing the company at a significant discount to its book value, which often occurs in biotech firms where tangible assets are undervalued compared to the potential of their intellectual property. Regarding alternative valuation measures, the Price to Sales is N/A due to lack of revenue, while the EV/EBITDA stands at 0.52, a figure that suggests the company's enterprise value is very low relative to its negative earnings, reflecting the high risk associated with its clinical-stage development status. The stock's price range over the last year has fluctuated between a 52-week low of $1.36 and a 52-week high of $35.20. Without a specific current price provided in the facts, the position relative to this range cannot be precisely calculated, but the wide spread indicates high price volatility typical of small-cap biotech stocks. The Beta value is 1.52, meaning the stock's price volatility is significantly higher than the broader market, amplifying both potential gains and losses for investors exposed to this high-risk asset.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company currently reports N/A for revenue and N/A for earnings growth. Since the company has not yet achieved commercial revenue, earnings cannot grow faster than revenue in a traditional sense, as the entire financial effort is directed toward converting clinical-stage devices like the Hemopurifier into marketable products rather than scaling sales. Aethlon Medical does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings—or rather, all available cash reserves—into growth initiatives such as clinical trials and device development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation, with all financial resources dedicated to sustaining operations and advancing the immunotherapeutic devices intended for cancer and viral infection treatments.